# An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer

Source: https://onco.cc/trials/nct06693336/  
OnCo record `nct06693336` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by ToLymph Inc., now recruiting.

## Summary

An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06693336 by ToLymph Inc., with 42 participants planned, started 2024-11-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: SMS001. Conditions listed: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06693336
- Phase: 2
- Setting: Phase IIa Trial Evaluating the Safety and Therapeutic Effect of SMS001 as an Adjuvant Therapy to Control Tumor Recurrence in Stage Ib-IIIa (N2) Non-Small Cell Lung Cancer (NSCLC) Patients
- Sponsor: ToLymph Inc.
- Enrolled: 42

## Sources

- ClinicalTrials.gov NCT06693336: https://clinicaltrials.gov/study/NCT06693336

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)

---
JSON: https://onco.cc/api/v1/entities/nct06693336.json